Originally published as JCO Early Release 10.1200/JCO.2005.02.8282 on December 12 2005

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gold, D. V. Articles by Goldenberg, D. M. Search for Related Content PubMed PubMed Citation Articles by Gold, D. V. Articles by Goldenberg, D. M. Social Bookmarking                            What's this?

New MUC1 Serum Immunoassay Differentiates Pancreatic Cancer From Pancreatitis

From the Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Belleville; Immunomedics Inc, Morris Plains, NJ; and the Department of Statistics, Columbia University, New York, NY

Address reprint requests to David V. Gold, PhD, Garden State Cancer Center, 520 Belleville Ave, Belleville, NJ 07109; e-mail: dvgold{at}gscancer.org

PURPOSE: To evaluate a new immunoassay for identification and quantitation of MUC1 in the sera of patients with pancreatic cancer or pancreatitis. The sensitivity and specificity of the assay are examined and compared to results from a CA19-9 immunoassay.

METHODS: An in vitro enzyme immunoassay was established with monoclonal antibody PAM4 as the capture reagent, and a polyclonal anti-MUC1 antibody as the probe. Patient sera were obtained from healthy, adult patients with acute and chronic pancreatitis, and those with pancreatic and other forms of cancer, and were measured for PAM4-reactive MUC1.

RESULTS: At a cutoff of 10.2 units/mL, 41 (77%) of 53 pancreatic cancer patients, none of the healthy individuals (n = 43), and only four (5%) of 87 patients with pancreatitis were positive above this value. Among nonpancreatic cancers investigated, colorectal cancers gave the highest percentage of positives (14%; five of 36). Overall, the sensitivity and specificity of the immunoassay for pancreatic cancer were 77% and 95%, respectively. Receiver operator characteristic analyses for discrimination of pancreatic cancer from pancreatitis provided an area under the curve of 0.89 (95% CI, 0.82 to 0.93), with a specificity of 95.4% and a positive likelihood ratio of 16.8. A direct pair-wise comparison of PAM4 and CA19-9 immunoassays for discrimination of pancreatic cancer and pancreatitis resulted in a significant difference (P < .003), with the PAM4 immunoassay demonstrating superior sensitivity and specificity.

CONCLUSION: The high sensitivity and specificity observed suggest that the PAM4-based immunoassay of circulating MUC1 may be useful in the diagnosis of pancreatic cancer.

Supported in part by grants CA92723 and CA98488 from the National Institutes of Health (Bethesda, MD).

Presented in part at the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. SALEK, P. MINARIKOVA, L. BENESOVA, V. NOSEK, R. STRNAD, M. ZAVORAL, and M. MINARIK Mutation Status of K-ras, p53 and Allelic Losses at 9p and 18q Are Not Prognostic Markers in Patients with Pancreatic Cancer Anticancer Res, May 1, 2009; 29(5): 1803 - 1810. [Abstract] [Full Text] [PDF]

				A. E. Szafranska, M. Doleshal, H. S. Edmunds, S. Gordon, J. Luttges, J. B. Munding, R. J. Barth Jr, E. J. Gutmann, A. A. Suriawinata, J. Marc Pipas, et al. Analysis of MicroRNAs in Pancreatic Fine-Needle Aspirates Can Classify Benign and Malignant Tissues Clin. Chem., October 1, 2008; 54(10): 1716 - 1724. [Abstract] [Full Text] [PDF]

				T. L. Tinder, D. B. Subramani, G. D. Basu, J. M. Bradley, J. Schettini, A. Million, T. Skaar, and P. Mukherjee MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma J. Immunol., September 1, 2008; 181(5): 3116 - 3125. [Abstract] [Full Text] [PDF]

				D. V. Gold Reply to the Letter to the Editor by Bara, et al Clin. Cancer Res., August 15, 2008; 14(16): 5306 - 5307. [Full Text] [PDF]

				D. V. Gold, D. M. Goldenberg, H. Karacay, E. A. Rossi, C.-H. Chang, T. M. Cardillo, W. J. McBride, and R. M. Sharkey A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma Cancer Res., June 15, 2008; 68(12): 4819 - 4826. [Abstract] [Full Text] [PDF]

				D. V. Gold, Z. Karanjawala, D. E. Modrak, D. M. Goldenberg, and R. H. Hruban PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma Clin. Cancer Res., December 15, 2007; 13(24): 7380 - 7387. [Abstract] [Full Text] [PDF]

				G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF]

				W. J. McBride, P. Zanzonico, R. M. Sharkey, C. Noren, H. Karacay, E. A. Rossi, M. J. Losman, P.-Y. Brard, C.-H. Chang, S. M. Larson, et al. Bispecific Antibody Pretargeting PET (ImmunoPET) with an 124I-Labeled Hapten-Peptide J. Nucl. Med., October 1, 2006; 47(10): 1678 - 1688. [Abstract] [Full Text] [PDF]